Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Alizapride→

Alizapride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
59338-93-1
Molecular formula
C16H21N5O2
Molecular weight
315.37 g/mol
Drug class
Dopamine D2-receptor antagonistsubstituted-benzamide antiemetic and prokinetic
Mechanism of action
Antagonises dopamine D2 receptors, including receptors in the chemoreceptor trigger zone, producing antiemetic activity; it also has prokinetic effects.
Indications / reported uses
  • Nausea and vomiting
  • Post-operative nausea and vomiting

Sources: IUPHAR/BPS Guide to Pharmacology · NCI Drug Dictionary

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Alizapride Environmental Risk Assessment (ERA) (the Alizapride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.